Don’t use credit cards like this!
Do you pay only the minimum amount due on your credit card? How can your debt burden increase just by paying the minimum amount due? Watch this video to know
Shares of Sun Pharmaceuticals Industries hit an over four-year high as they rallied over 10% to Rs 774 on the BSE in intra-day trade on Friday after the company reported strong results for the June quarter (Q1FY22). The pharma major on July 30 reported a net profit of Rs 1,444.1 crore in the quarter ended Q1FY22 against a loss of Rs 1,655.6 crore in the year-ago period.
The company’s revenue was up 28.2% at Rs 9,669.4 crore against Rs 7,582.5 crore, year-on-year (YoY). EBITDA (earnings before interest, tax, depreciation, and amortisation) was up 53.3% at Rs 2,821 crore versus Rs 1,840.6 crore and the margin was up at 29% against 24.3%, YoY.
The management said the company witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products. The management is enthused by the all-around growth across all businesses compared to Q4 last year. “We continue to focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent in-licensing of Winlevi for the US and Canada is a step forward in this direction,” Dilip Shanghvi, Managing Director of Sun Pharma said.
At 3:27 the shares were trading 774.75 apiece gaining as much as 10.17%. On an intraday basis, it made a high of Rs 780.10.